WorldMarketStudy announces it Will Carry GlobalData’s Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016 June reports in its store.

Browse complete report at http://www.worldmarketstudy.com/market-report/hemophilia-drug-pipeline-analysis-market-forecasts-2016-500.html

GlobalData’s pharmaceutical and healthcare report, “Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global hemophilia market was valued at $6.5 billion in 2009. This slow growth is primarily attributed to a low diagnosis rate and the high price of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX from Baxter Laboratories. BeneFIX is a clotting factor IX.

Scope

The scope of the report includes:

  • Annualized global hemophilia market revenues data from 2001 to 2009, forecast for seven years to 2016.
  • Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
  • Pipeline analysis data providing a split across different phases by the mechanism of action being developed and the emerging trends. The key classes of mechanism of action include substitution of coagulation factor VIII, increasing clotting factor VIII, plasma-derived FVIII.
  • Analysis of the current and future market competition in the global hemophilia market. The key market players covered are PTC Therapeutics, Recoly N.V., Novo Nordisk.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global haemophilia market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global haemophilia market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global haemophilia market landscape? – Identify, understand and capitalize

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Hemophilia Market: Market Characterization
2.1 Overview
2.2 Hemophilia Therapeutics Market Size
2.3 Hemophilia Therapeutics Market Forecast and CAGR
2.4 Drivers and Barriers for the Hemophilia Therapeutics Market
2.4.1 Drivers for the Hemophilia Therapeutics Market
2.4.2 Barriers for the Hemophilia Therapeutics Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 Hemophilia Therapeutics Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in the Hemophilia Therapeutics Market
3.3.1 NovoSeven
3.3.2 Kogenate FS
3.3.3 Xyntha
3.3.4 Advate
3.4 Key Takeaway

4 Hemophilia Therapeutics Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytic Framework
4.3 Hemophilia Therapeutics – Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 Ataluren (PTC124)
4.4.2 NecLip-rFVIIa (LongSeven)
4.4.3 rFVIII (Recombinant factor VIIa (N8))
4.5 Hemophilia Therapeutics Market – Clinical Pipeline by Mechanism of Action
4.6 Hemophilia Therapeutics Pipeline – Pipeline by Clinical Phase of Development
4.6.1 Hemophilia Therapeutics – Phase III Clinical Pipeline
4.6.2 Hemophilia Therapeutics – Phase II Clinical Pipeline
4.6.3 Hemophilia Therapeutics – Phase I Clinical Pipeline
4.6.4 Hemophilia Therapeutics – Pre-clinical Pipeline
4.7 Key Takeaway

5 Hemophilia Therapeutics Market: Implications for Future Market Competition

6 Hemophilia Therapeutics Market: Future Players in the Hemophilia Therapeutics Market
6.1 Introduction
6.2 PTC Therapeutics
6.2.1 Overview
6.2.2 Hemophilia Portfolio
6.2.3 Hemophilia Pipeline Portfolio
6.2.4 Ataluren (PTC124)
6.3 Recoly N.V.
6.3.1 Overview
6.3.2 Hemophilia Portfolio
6.3.3 Hemophilia Pipeline Portfolio
6.3.4 NecLip-rFVIIa (LongSeven)
6.4 Novo Nordisk
6.4.1 Overview
6.4.2 Hemophilia Portfolio
6.4.3 Hemophilia Pipeline Portfolio
6.4.4 rFVIII (Recombinant factor VIIa (N8))

7 Hemophilia Therapeutics Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

1.1 List of Tables
Table 1: Hemophilia Therapeutics Market, Global, Revenues ($bn), 2001-2009
Table 2: Hemophilia Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016
Table 3: Major Marketed Products Comparison in the Hemophilia Therapeutics Market, 2010
Table 4: Hemophilia Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 5: Hemophilia Therapeutics – Phase III Clinical Pipeline, 2010
Table 6: Hemophilia Therapeutics – Phase II Clinical Pipeline, 2010
Table 7: Hemophilia Therapeutics – Phase I Clinical Pipeline, 2010
Table 8: Hemophilia Therapeutics – Pre-Clinical Pipeline, 2010
Table 9: PTC Therapeutics, Inc. – Hemophilia Pipeline Products, 2010
Table 10: Recoly N.V. – Hemophilia Pipeline Products, 2010
Table 11: Novo Nordisk – Hemophilia Pipeline Products, 2010

1.2 List of Figures
Figure 1: Hemophilia Therapeutics Market, Global, Revenues ($bn), 2001-2009
Figure 2: Hemophilia Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016
Figure 3: Opportunity and Unmet Need in the Hemophilia Therapeutics Market, 2010
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Hemophilia Therapeutics, 2010
Figure 5: Technology Trends Analytic Framework of the Hemophilia Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the Hemophilia Therapeutics Pipeline – Description, 2010
Figure 7: Hemophilia Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action (%), 2010
Figure 8: Hemophilia Therapeutics Pipeline by Phase of Clinical Development, 2010
Figure 9: Implications for Future Market Competition in the Hemophilia Therapeutics Market, 2010
Figure 10: Hemophilia Therapeutics Market – Clinical Pipeline by Company (No. of Molecules), 2010
Figure 11: GlobalData Methodology, 2010
Figure 12: GlobalData Market Forecasting Model, 2010

View All Pharmaceuticals Market Reports http://www.worldmarketstudy.com/Pharmaceuticals-market-research-4.html

About WorldMarketStudy
In these days of cut-throat market competition, sole reliance on instincts is a dangerous proposition for any business person. Successful business can only be built on the solid background of well-researched information and knowledge based decisions.

And to aid these vital decisions, we at WorldMarketStudy offer you a one point solution for all your market research requirements. We have compiled a huge and constantly updated repository of more than 200,000 market search reports collected from over 650 research reports publishers. Browse all reports at http://www.worldmarketstudy.com/

Contact
Jessica Thomas
WorldMarketStudy
+91-9881144324
http://www.worldmarketstudy.com/
http://worldmarketstudy.wordpress.com/
http://worldmarketstudy.blogspot.com/